Biodexa Pharmaceuticals Releases 2024 Annual Report and Announces AGM

Biodexa Pharmaceuticals ( (BDRX) ) has provided an update.

On May 23, 2025, Biodexa Pharmaceuticals PLC announced the release of its Annual Report for the year ending December 31, 2024, and distributed a Notice of Annual General Meeting to shareholders. The meeting is scheduled for June 26, 2025, in Cardiff, Wales, and proxy forms have been provided to holders of both ordinary shares and American Depositary Shares. This announcement is a routine part of the company’s annual governance process, ensuring transparency and shareholder engagement.

The most recent analyst rating on (BDRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.

Spark’s Take on BDRX Stock

According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral.

Biodexa Pharmaceuticals has a low overall stock score of 45, driven by significant financial challenges, bearish technical indicators, and a poor valuation. The lack of positive earnings guidance further adds to the uncertainty. The company must improve financial performance and operational efficiency to enhance investor confidence.

To see Spark’s full report on BDRX stock, click here.

More about Biodexa Pharmaceuticals

Biodexa Pharmaceuticals PLC operates in the pharmaceutical industry, focusing on the development and commercialization of innovative medical treatments. The company is headquartered in Cardiff, United Kingdom, and engages in producing pharmaceutical products with a market focus on both ordinary shares and American Depositary Shares.

Average Trading Volume: 2,525,631

Technical Sentiment Signal: Sell

Current Market Cap: $929.3K

Find detailed analytics on BDRX stock on TipRanks’ Stock Analysis page.